Three-year and 5 year progression-free survival (PFS) and overall survival (OS) rates by stage group and response to primary treatment*
| Response to primary treatment | Early-stage disease | Locally advanced disease | Advanced disease | P value |
| Complete response | ||||
| 3-year PFS | 72% (64% to 81%) | 48% (39% to 57%) | 28% (7% to 48%) | <0.0001 |
| 5-year PFS | 68% (59% to 78%) | 42% (33% to 51%) | 19% (0% to 39%) | |
| 3-year OS | 91% (86% to 97%) | 63% (54% to 71%) | 53% (29% to 77%) | <0.0001 |
| 5-year OS | 78% (69% to 87%) | 52% (43% to 61%) | 39% (15% to 64%) | |
| Partial response | ||||
| 3-year OS | NA | 100% (NA-100%) | 100% (0% to 100%) | 0.8651 |
| 5-year OS | NA | 100% (0% to 100%) | 100% (0% to 100%) | |
| Stable disease | ||||
| 3-year OS | NA | 13% (0% to 35%) | 13% (0% to 35%) | 0.1823 |
| 5-year OS | NA | 13% (0% to 35%) | 13% (0% to 35%) | |
| Mixed response or progressive disease or new disease | ||||
| 3-year OS | 35% (11% to 60%) | 9% (2% to 17%) | 3% (0% to 8%) | 0.0012 |
| 5-year OS | 21% (0% to 42%) | 2% (0% to 6%) | 3% (0% to 8%) |
*Values in table are rate (95% CI).